题名

推動消除C肝政策之回顧

并列篇名

Implementation of hepatitis C policies in Taiwan

DOI

10.6288/TJPH.202304_42(2).112006

作者

楊雯雯(Wen-Wen Yang)；劉嘉玲(Chia-Ling Liu)；吳慧敏(Grace Hui-Min Wu)；鄭國本(Kuo-Pen Cheng)；盧勝男(Sheng-Nan Lu)；簡榮南(Rong-Nan Chien)；蒲若芳(Raoh-Fang Pwu)

关键词

慢性C型肝炎 ； 國家消除C肝政策綱領 ； 國家消除C肝辦公室 ； 消除C肝 ； 篩檢 ； chronic hepatitis C (HCV) ； Taiwan Hepatitis C Policy Guideline ； Taiwan National Hepatitis C Program Office (TWNHCP) ； elimination of hepatitis C ； screening

期刊名称

台灣公共衛生雜誌

卷期/出版年月

42卷2期（2023 / 04 / 28）

页次

165 - 179

内容语文

繁體中文;英文
中文摘要

為滿足我國C肝防治需求及呼應世界衛生組織消除C肝的目標，衛生福利部於2016年12月成立「國家C型肝炎旗艦計畫辦公室」，並於2019年12月更名為「國家消除C肝辦公室」，以展現政府決心及消除C肝之承諾。為能更有效地溝通及協調相關政策，辦公室蒐集全國的C肝流行病學概況及臨床特徵等實證資料，並在肝病、流病、經濟專家、公衛官員及署司首長的指導下，在2019年5月公布「國家消除C肝政策綱領2018-2025」。綱領設立2025年消除C肝之願景，錨定三大核心策略、三大政策方向及八大行動方針，讓各界理解政府的施政目標及方向，以利各界辦理消除C肝活動時能有依循。本文旨在彙整這幾年來中央與地方政府結合民間資源，在公私協力下的作為與進展，包括確保充足的預算；降低C肝防治障礙，提高服務可近性，落實防治一條龍；落實精準篩檢及診治策略；推動高風險族群C肝防治；加強C肝識能；政策成效評估；鼓勵研究發展與引進有效之篩檢診斷工具等面向。
英文摘要

The Taiwan National Hepatitis C Program Office has been established since December 2016 by the Ministry of Health and Welfare of Taiwan, to respond to the society's calling for a national policy on hepatitis C control, as well as being the first step toward the WHO’s goal set on 2015. Aimed to more effective on communicating and coordinating related policies, the Office gathered information about epidemiological profile and clinical characteristics of hepatitis C nationwide and, with the advice and guidance provided by experts from hepatologists, epidemiologists, economists, public health officers, and government leaders, the "Taiwan Hepatitis C Policy Guideline 2018-2025" was formulated and announced in May 2019. The Guideline set up a goal of hepatitis C elimination by 2025 and highlighted three policy directions, three core strategies, eight action plans that could be implemented by relevant stakeholders at all levels of governments and across public and private sectors. This article aims to summarize the activities which have been implemented as of to date - from the central and local governments, or public and private sectors. These activities include securing adequate budget; lowering barriers of access to care; maintaining continuum of care to leave no one behind; implementing precision screening and diagnosis and treatment strategies; promoting the interventions and strategies among high-risk groups; raising the public awareness on HCV screening and treatment; evaluating outcomes of policy and interventions; encouraging R&D and the introduction of HCV screening and in vitro diagnostic kits products as well.
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. 吳慧敏, GHM,楊雯雯, WW,劉嘉玲, CL(2021)。台灣2025年C肝消除的策略與進度。台灣衛誌，40，1-4。
    連結：
  2. 楊雯雯, WW,吳慧敏, GHM,盧勝男, SN,劉嘉玲, CL,鄭國本, KP,蒲若芳, RF(2022)。滾動調整 2025 年 C 肝消除治療目標數。台灣衛誌，41，567-571。
    連結：
  3. 盧勝男, SN,吳慧敏, GHM,蒲若芳, RF(2021)。依據流行病學的精準C肝防治先導計劃引領全國性篩檢。台灣衛誌，40，123-126。
    連結：
  4. Chang, C,Hung, CH,Wang, JH,Lu, SN(2018).Hepatitis C core antigen highly correlated to HCV RNA.Kaohsiung J Med Sci,34,684-688.
  5. Chang, TS,Chang, KC,Chen, WM(2021).Village-to-village screening for hepatitis B and C using quantitative HBsAg and anti-HCV testing with reflex HCV core antigen tests in the remote communities of a resource-rich setting: a population-based prospective cohort study.BMJ Open,11,e046115.
  6. Chen, CH,Yang, PM,Huang, GT,Lee, HS,Sung, JL,Sheu, JC.(2007).Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants.J Formos Med Assoc,16,148-155.
  7. Chen, CT,Lu, MY,Hsieh, MH(2022).Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.World J Gastroenterol,28,263-274.
  8. Chen, DS(2019).Taiwan commits to eliminating hepatitis C in 2025.Lancet Infect Dis,19,466-467.
  9. Chen, GJ,Ho, SY,Su, LH(2022).Hepatitis C microelimination among people living with HIV in Taiwan.Emerg Microbes Infect,11,1664-1671.
  10. Chen, HF,Li, CY,Chen, P,See, TT,Lee, HY(2006).Seroprevalence of hepatitis B and C in type 2 diabetic patients.J Chin Med Assoc,69,146-152.
  11. Chen, WM,Lee, CY,Hsu, NT(2021).Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community.J Formos Med Assoc,120,1237-1241.
  12. Chien, RN,Lu, SN,Pwu, RF,Wu, GHM,Yang, WW,Liu, CL(2021).Taiwan accelerates its efforts to eliminate hepatitis C.Glob Health Med,3,293-300.
  13. Chien, RN,Lu, SN,Wu, GHM(2023).Policy and strategy of HCV elimination at national level: experience in Taiwan.J Infect Dis
  14. Fleurence, RL,Collins, FS(2023).A national hepatitis C elimination program in the united states: a nistoric opportunity.JAMA,329,1251-1252.
  15. Hong, CM,Lin, YY,Liu, CJ(2021).Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan.Viruses,13,2294.
  16. Hu, TH,Su, WW,Yang, CC(2021).Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan.Am J Kidney Dis,78,511-519.e1.
  17. Hu TH, Su WW, Yang CC, et al. The International Liver Congress 2021 (EASL) -- Changhua-Integrated Program to Stop Hepatitis C Infection (CHIPS-C) of Taiwan (PO-2103). Available at: https://www.postersessiononline.eu/173580348_eu/congresos/ILC2021/aula/-PO_2103_ILC2021.pdf. Accessed December 18, 2022.
  18. Huang, JF,Hsieh, MY,Wei, YJ(2022).Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).Hepatol Int,16,59-67.
  19. Huang, WC,Lin, YC,Chen, PJ(2022).Community-based screening for hepatitis B and C infectivity using two quantitative antigens to identify endemic townships.Viruses,14,304.
  20. Hui, JM,Sud, A,Farrell, GC(2003).Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].Gastroenterology,125,1695-1704.
  21. Kee, KM,Chen, WM,Hsu, NT(2022).Communitybased screening by Anti-HCV reflex HCV Ag test and accessible post-screening care toward elimination of hepatitis C in two hyperendemic townships.J Formos Med Assoc,121,1850-1856.
  22. Lazarus, JV,Safreed-Harmon, K,Thursz, MR(2018).The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations.Semin Liver Dis,38,181-192.
  23. Lee, JJ,Lin, MY,Chang, JS(2014).Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis.PLoS One,9,e100790.
  24. Lee, MH,Yang, HI,Wang, CH(2010).Hepatitis C virus infection and increased risk of cerebrovascular disease.Stroke,41,2894-2900.
  25. National Academies of Sciences, Engineering, and Medicine(2017).A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report.Washington, DC:The National Academies Press.
  26. Petta, S(2017).Hepatitis C virus and cardiovascular: a review.J Adv Res,8,161-168.
  27. Sheen, YJ,Hsu, CC,Kung, PT,Chiu, LT,Tsai, WC(2022).Impact of chronic hepatitis on cardiovascular events among type 2 diabetes patients in Taiwan pay-for-performance program.Sci Rep,12,11720.
  28. Su WW, Yang CC, Chang WJ, et al. Toward hepatitis C elimination in marginalized populations by a collaborative multi-setting approach in Taiwan. Available at: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4022233. Accessed December 18, 2022.
  29. Sun, HY,Chiang, C,Huang, SH(2022).Three-stage pooled plasma hepatitis C virus RNA testing for the identification of acute HCV infections in at-risk populations.Microbiol Spectr,10,e0243721.
  30. Sun, HY,Liu, WD,Wang, CW(2022).Performance of hepatitis C Virus (HCV) core antigen assay in the diagnosis of recently acquired HCV infection among high-risk populations.Microbiol Spectr,10,e0034522.
  31. Tien, HM,Cheng, TC,Lien, HC(2022).Liver disease screening and hepatitis C virus elimination in Taiwan rural indigenous townships: village-by-village screening and linking to outreach hepatology care.Int J Environ Res Public Health,19,3269.
  32. U.S. Food and Drug Administration (US FDA). SOVALDI (sofosbuvir) tablets, for oral use Initial U.S. Approval: 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. Accessed March 13, 2023.
  33. US FDA. HARVONI (ledipasvir and sofosbuvir) tablets, for oral use Initial U.S. Approval: 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf. Accessed March 13, 2023.
  34. US FDA. Medical review(s), HARVONI (ledipasvir and sofosbuvir) tablets. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000MedR.pdf. Accessed March 13, 2023.
  35. US FDA. Medical review(s), SOVALDI sofosbuvir tablets. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000MedR.pdf. Accessed March 13, 2023.
  36. Wang, JH,Chen, CH,Chang, CM,Feng, WC,Lee, CY,Lu, SN(2020).Hepatitis C virus core antigen is cost-effective in community-based screening of active hepatitis C infection in Taiwan.J Formos Med Assoc,119,504-508.
  37. Wei, YJ,Hsu, PY,Lee, JJ(2021).Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan -- the Formosa-Like Group.J Viral Hepat,28,719-727.
  38. WHO(2016).Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief.Geneva:WHO.
  39. WHO(2017).WHO Guidelines on Hepatitis B and C Testing.Geneva:WHO.
  40. Wu, GHM,Pwu, RF,Chen, SC(2018).Achieving hepatitis C elimination in Taiwan -- overcoming barriers by setting feasible strategies.J Formos Med Assoc,117,1044-1045.
  41. Wu, GHM,Pwu, RF,Chen, SC,Chen, DS(2020).Taiwan is on track of accelerating hepatitis C elimination by 2025.Liver Int,40,1506-1507.
  42. Wu, GHM,Yang, WW,Liu, CL(2021).The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: a nationwide study.J Formos Med Assoc,120,1444-1451.
  43. Yang, TH,Fang, YJ,Hsu, SJ(2020).Microelimination of chronic hepatitis C by universal screening plus direct-acting antivirals for incarcerated persons in Taiwan.Open Forum Infect Dis,7,ofaa301.
  44. Yu, ML,Yeh, ML,Tsai, PC(2015).Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Medicine,94,e690.
  45. 台灣消化系醫學會：C型肝炎全口服抗病毒藥物治療C型肝炎線上教育課程。http://www.gest.org.tw/health/content.php?type=&id=2&pageNo=1&continue=Y。引用2022/12/18。 The Gastroenterological Society of Taiwan. Online educational course on full oral antiviral drug treatment for hepatitis C. Available at: http://www.gest.org.tw/health/content.php?type=&id=2&pageNo=1&continue=Y. Accessed December 18, 2022. [In Chinese]
  46. 吳慧敏, GHM,楊雯雯, WW,吳慧敏, GHM,鄭國本, KP,蒲若芳, RF(2019)。台灣C型肝炎消除的國家政策與軌跡。愛之關懷季刊，109，6-16。
  47. 社團法人中華民國糖尿病學會：2019台灣糖尿病腎臟疾病臨床照護指引。http://www.endo-dm.org.tw。引用2022/12/18。 The Diabetes Association of the Republic of China (Taiwan). 2019 Taiwan clinical practice guideline for diabetic kidney disease. Available at: http://www.endo-dm.org.tw. Accessed December 18, 2022. [In Chinese]
  48. 社團法人中華民國糖尿病學會：2022第2型糖尿病臨床照護指引。http://www.endo-dm.org.tw。引用2022/12/18。 The Diabetes Association of the Republic of China (Taiwan). DAROC clinical practice guidelines for type 2 diabetes care 2022. Available at: http://www.endo-dm.org.tw. Accessed December 18, 2022. [In Chinese]
  49. 洪瑄佑, HY,林慧娟, HC(2019)。慢性C型肝炎之健保給付新藥探討。藥學雜誌，35，2-10。
  50. 財政部賦稅署：法規查詢主題專區：核釋西醫師依C肝執行計畫取得屬C肝藥品費用之健保收入其成本費用計算規定。https://law.dot.gov.tw/law-ch/home.jsp?id=18&parentpath=0,7&mcustomize=newlaw_view.jsp&dataserno=201904120001。引用2022/12/18。 Taxation Adminstration, Ministry of Finance, R.O.C. Law source ratrieving system of taxation laws and regulations: request for the higher authority to interpret the calculation rules for the cost of hepatitis C drug-related NHI income obtained by Western physicians according to the hepatitis C Implementation Plan. Available at: https://law.dot.gov.tw/law-ch/home.jsp?id=18&parentpath=0,7&mcustomize=newlaw_view.jsp&dataserno=201904120001. Accessed December 18, 2022. [In Chinese]
  51. 國家發展委員會：國家發展委員會第56次委員會議紀錄。https://www.ndc.gov.tw/nc_3660_29943。引用2022/12/18。National Development Council. Meeting minutes of the 56th meeting of the National Development Council Committee. Available at: https://www.ndc.gov.tw/nc_3660_29943. Accessed December 18, 2022. [In Chinese]
  52. 劉俊人, CJ,許景盛, CH,高嘉宏, JH(2012)。慢性 C 型肝炎治療的新進展：從干擾素到直接抗病毒藥物。內科學誌，23，383-391。
  53. 衛生福利部： C 型肝炎原鄉全治計畫專區。https://www.mohw.gov.tw/lp-4463-1.html。引用2022/12/18。 Ministry of Health and Welfare, R.O.C. (Taiwan). Hepatitis C Comprehensive Treatment Project Area for indigenous people. Available at: https://www.mohw.gov.tw/lp-4463-1.html. Accessed December 18, 2022. [In Chinese]
  54. 衛生福利部中央健康保險署：106年度C型肝炎全口服新藥健保給付執行計畫。https://www.nhi.gov.tw/Resource/bulletin/6811_1060034779-3.pdf。引用2023/03/13。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). NHI Payment Implementation Plan for New Oral Drugs for Treating Hepatitis C. Available at: https://www.nhi.gov.tw/Resource/bulletin/6811_1060034779-3.pdf. Accessed March 13, 2023. [In Chinese]
  55. 衛生福利部中央健康保險署：C型肝炎全口服新藥健保給付執行計畫。https://www.nhi.gov.tw/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979。引用2022/12/18。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). NHI Payment Implementation Plan for New Oral Drugs for Treating Hepatitis C. Available at: https://www.nhi.gov.tw/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979. Accessed December 18, 2022. [In Chinese]
  56. 衛生福利部中央健康保險署：有關「C型肝炎全口服抗病毒藥物治療C型肝炎線上教育課程」。http://www.gest.org.tw/health/content.php?type=&id=2&pageNo=1&continue=Y。引用2022/12/18。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Online educational course on full oral antiviral drug treatment for hepatitis C. Available at: http://www.gest.org.tw/health/content.php?type=&id=2&pageNo=1&continue=Y. Accessed December 18, 2022. [In Chinese]
  57. 衛生福利部中央健康保險署：全民健康保險門診透析總額支付制度品質確保方案。https://www.nhi.gov.tw/Resource/webdata/Attach_10895_2_6.3.1%EF%BC%9A%E5%93%81%E8%B3%AA%E7%A2%BA%E4%BF%9D%E6%96%B9%E6%A1%88-%E6%A9%AB%E5%BC%8F960806.pdf。引用2022/12/18。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Quality Assurance Plan for NHI Outpatient Dialysis Total Payment System. Available at: https://www.nhi.gov.tw/Resource/webdata/Attach_10895_2_6.3.1%EF%BC%9A%E5%93%81%E8%B3%AA%E7%A2%BA%E4%BF%9D%E6%96%B9%E6%A1%88-%E6%A9%AB%E5%BC%8F960806.pdf. Accessed December 18, 2022. [In Chinese]
  58. 衛生福利部中央健康保險署：健保醫字第1100034039號。https://www.nhi.gov.tw/。引用2023/01/31。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Document code Jian-Bao-Yi-Zi No. 1100034039 issued by National Health Insurance Administration. Available at: https://www.nhi.gov.tw/. Accessed January 31, 2023. [In Chinese]
  59. 衛生福利部中央健康保險署：公告修訂C型肝炎全口服新藥健保給付執行計畫。https://www.nhi.gov.tw/BBS_Detail.aspx?n=73CEDFC921268679&sms=D6D5367550F18590&s=B1AC08D6C9759EFE。引用2022/12/18。 National Health Insurance Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Announcement of the revised NHI Payment Implementation Plan for New Oral Drugs for Treating Hepatitis C. Available at: https://www.nhi.gov.tw/BBS_Detail.aspx?n=73CEDFC921268679&sms=D6D5367550F18590&s=B1AC08D6C9759EFE. Accessed December 18, 2022. [In Chinese]
  60. 衛生福利部心理及口腔衛生司：公開徵求補助辦理衛生福利部111-112年度「美沙冬治療品質提升試辦計畫」，公告時間自即日起至110年12月14日止。https://dep.mohw.gov.tw/DOMHAOH/cp-4097-64130-107.html。引用2022/12/18。 Department of Mental and Oral Health, Ministry of Health and Welfare, R.O.C. (Taiwan). Call for subsidizing MOHW 2022-2023 Pilot Project for Mesadone Treatment Quality Improvement until December 14, 2021. Available at: https://dep.mohw.gov.tw/DOMHAOH/cp-4097-64130-107.html. Accessed December 18, 2022. [In Chinese]
  61. 衛生福利部心理健康司：衛生福利部111年藥癮治療費用補助方案。https://dep.mohw.gov.tw/DOMHAOH/cp-4097-64677-107.html。引用2022/12/18。 Department of Mental Health, Ministry of Health and Welfare, R.O.C. (Taiwan). MOHW 2022 Drug Addiction Treatment Subsidy Project. Available at: https://dep.mohw.gov.tw/DOMHAOH/cp-4097-64677-107.html. Accessed December 18, 2022. [In Chinese]
  62. 衛生福利部食品藥物管理署：安倍多標的C肝病毒抗體快速檢驗套組仿單（衛部醫器輸字第028922號），2016。https://udid.fda.gov.tw/index.aspx。引用2023/01/31。 Food and Drug Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). MP Diagnostics Multisure HCV Antibody Assay Manual (MOHW Medical Equipment Input No. 028922), 2016. Available at: https://udid.fda.gov.tw/index.aspx. Accessed January 31, 2023. [In Chinese]
  63. 衛生福利部食品藥物管理署：圖優C型肝炎抗體快篩仿單（衛部醫器輸字第035674號），2022。https://udid.fda.gov.tw/index.aspx。引用2023/01/31。 Food and Drug Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Tuyou Hepatitis C Antibody Rapid Screening Manual (MOHW Medical Equipment Input No. 035674), 2022. Available at: https://udid.fda.gov.tw/index.aspx. Accessed January 31, 2023. [In Chinese]
  64. 衛生福利部食品藥物管理署：詩丹C型肝炎抗體快篩仿單（衛部醫器輸字第035896號），2023。https://udid.fda.gov.tw/index.aspx。引用2023/01/31。 Food and Drug Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Shidan Hepatitis C Antibody Rapid Screening Manual (MOHW Medical Equipment Input No. 035896), 2023. Available at: https://udid.fda.gov.tw/index.aspx. Accessed January 31, 2023. [In Chinese]
  65. 衛生福利部國民健康署：有關成人預防保健服務B、C型肝炎檢查醫師資格。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=14970&sid=13580。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Qualifications of physicians for provision of adult preventive health services on hepatitis B and C examination. Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=14970&sid=13580. Accessed December 18, 2022. [In Chinese]
  66. 衛生福利部國民健康署：好康報你知(健康檢查補助)問答集─「成人預防保健『健康加值』方案」當中，B、C型肝炎篩檢之提供方式及實施對象。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=814&pid=4496&sid=4495。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Q & A on health examination subsidies: hepatitis B and C screening provision methods and targets of screening services according to the Adult Preventive Health Care Added Value Program. Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=814&pid=4496&sid=4495. Accessed December 18, 2022. [In Chinese]
  67. 衛生福利部國民健康署：衛授國字第1100600130號。https://www.hpa.gov.tw/Home/Index.aspx。引用2023/01/31。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Document code Wei-Shou-Guo-Zi No. 1100600130 issued by Health Promotion Administration. Available at: https://www.hpa.gov.tw/Home/Index.aspx. Accessed January 31, 2023. [In Chinese]
  68. 衛生福利部國民健康署：衛授國字第1090600862號。https://www.hpa.gov.tw/Home/Index.aspx。引用2023/01/31。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Document code Wei-Shou-Guo-Zi No. 1090600862 issued by Health Promotion Administration. Available at: https://www.hpa.gov.tw/Home/Index.aspx. Accessed January 31, 2023. [In Chinese]
  69. 衛生福利部國民健康署：為配合國家消除C肝政策，自108年6月1日起調整成人預防保健服務之具原住民身分民眾B、C型肝炎篩檢年齡為40歲至60歲終身一次。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4074&pid=11476。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). In coordination with the national policy to eliminate hepatitis C, starting from Jun 1, 2019, the eligible age of hepatitis B and C screening for people with indigenous identity in adult preventive health care services shall be adjusted to once in lifetime between the ages of 40 and 60. Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=4074&pid=11476. Accessed December 18, 2022. [In Chinese]
  70. 衛生福利部國民健康署：醫事服務機構辦理預防保健服務注意事項。https://www.tma.tw/doc/1198%E6%94%B6%E6%96%87_%E9%99%84%E4%BB%B61.pdf。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Precautions for medical service institutions in handling preventive health care services. Available at: https://www.tma.tw/doc/1198%E6%94%B6%E6%96%87_%E9%99%84%E4%BB%B61.pdf. Accessed December 18, 2022. [In Chinese]
  71. 衛生福利部國民健康署：調整單獨提供成人預防保健服務B、C型肝炎檢查之檢查紀錄結果表單必填欄位。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=15670。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Adjustment in required fields on the sheet of the hepatitis B and C examination results for adult preventive health care services. Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=15670. Accessed December 18, 2022. [In Chinese]
  72. 衛生福利部國民健康署：好康報你知(健康檢查補助)問答集—請問B、C型肝炎檢查的條件和年齡。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=814&pid=7536&sid=4496。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Q & A on health examination subsidies: what are the eligibility and age for hepatitis B and C examination? Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=814&pid=7536&sid=4496. Accessed December 18, 2022. [In Chinese]
  73. 衛生福利部國民健康署：為配合國家消除C肝政策，自109年9月2 8日起調整成人預防保健服務B、C型肝炎篩檢年齡為45歲至7 9歲終身一次。https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=13580。引用2022/12/18。 Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). In coordination with the national policy to eliminate hepatitis C, starting from Sep 28, 2020, the eligible age of hepatitis B and C screening for people with indigenous identity in adult preventive health care services shall be adjusted to once in lifetime between the ages of 45 and 79. Available at: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=1115&pid=13580. Accessed December 18, 2022. [In Chinese]
  74. 衛生福利部國家消除C肝辦公室：健保口服C肝新藥使用情形與治療成效。https://www.mohw.gov.tw/cp-4465-62953-1.html。引用2022/12/18。 Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare, R.O.C. (Taiwan). Use and therapeutic effect of new oral drugs for hepatitis C. Available at: https://www.mohw.gov.tw/cp-4465-62953-1.html. Accessed December 18, 2022. [In Chinese]
  75. 衛生福利部國家消除C肝辦公室：消除C肝進度監測平台。https://www.mohw.gov.tw/dl-77667-ed4abe35-39b9-4f7b-ab44-8683becefb11.html。引用2022/12/18。 Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare, R.O.C. (Taiwan). Taiwan National Hepatitis C Elimination Progress Monitoring Information Network. Available at: https://www.mohw.gov.tw/dl-77667-ed4abe35-39b9-4f7b-ab44-8683becefb11.html. Accessed December 18, 2022. [In Chinese]
  76. 衛生福利部國家消除C肝辦公室：衛生福利部107年度「慢性C型肝炎病人接受口服抗病毒藥物治療失敗原因探討」補（捐）助科技發展計畫徵求說明書。https://www.mohw.gov.tw/cp-18-45650-1.html。引用2022/12/18。 Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare, R.O.C. (Taiwan). Solicitation of subsidizing the science and technology development plan regarding MOHW 2018 discussion on the causes of treatment failure in patients with chronic hepatitis C who took oral antiviral drugs. Available at: https://www.mohw.gov.tw/cp-18-45650-1.html. Accessed December 18, 2022. [In Chinese]
  77. 衛生福利部國家消除C肝辦公室：國家消除C肝政策綱領2018-2025。https://www.mohw.gov.tw/cp-4464-49019-1.html。引用2023/03/13。 Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare, R.O.C. (Taiwan). Taiwan hepatitis C policy guideline 2018-2025. Available at: https://www.mohw.gov.tw/cp-4464-49019-1.html. Accessed March 13, 2023. [In Chinese]
  78. 衛生福利部國家消除C肝辦公室：台灣C肝風險潛勢地圖。https://www.mohw.gov.tw/cp-4464-52812-1.html。引用2022/12/18。 Taiwan National Hepatitis C Program Office, Ministry of Health and Welfare, R.O.C. (Taiwan). Map of hepatitis C risks in Taiwan. Available at: https://www.mohw.gov.tw/cp-4464-52812-1.html. Accessed December 18, 2022. [In Chinese]
  79. 顧心嬿, SY,甘淑婷, SY,謝慧婷, HT(2022)。高危險族群C型肝炎快速篩檢之分析（P050）。衛生福利部111年第十一屆提升全人醫療整合服務研討會，台南=Tainan:
print cancel